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Type 2 diabetes is a major public health problem with high and increasing prevalence, morbidity and 
mortality. The association between diabetes and microvascular and macrovascular complications is 
well known besides,  tight glycemic control is a necessity. HbA1C has clinically been used since 1980s 
as a gold standard for monitoring glycemic control and predicting of diabetic complications. 
The present review article was prepared by computerized sources of literature searches 2000 - 2009.
The history of Hemoglobin A1C, its assay techniques, optimal A1C targets, its reliability in control of 
diabetic complications, limitations of test results and its importance in control of diabetes patients and 
their complications are discussed.  
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Diabetes is a major health concern at worldwide 
and   despite   increasing   diagnostic   techniques, 
knowledge about its effects on public health and 
complex complications in current life of diabetic 
patients, only modest progression has been achieved 
in glycemic control. On the other hand, hemoglobin 
A1C  (HbA1C) is an important index of glycemic 
management   (Brownlee   &   Hirsch,   2006).   High 
levels   of   A1C  is   associated   with   high   risk   of 
peripheral arterial diseases even among individuals 
without   diabetes   (with   A1C  levels   5.3%   -   6%). 
Therefore, efforts to reduce the levels of A1C may 
reduce  the risk of these complications  (Day & 
Bailey,  2007;  Munter et al.,  2005; Selvin et al., 
2006). A trial on  2412 diabetic and nondiabetic 
patients   with   symptomatic   chronic   heart   failure 
showed   that   the   A1C  level   is   an   independent 
progressive   risk  factor   for   cardiovascular   death, 
hospitalization for heart failure, and total mortality 
(Gerstein et al., 2008; Qaseem et al., 2007). Another 
large study on 47904 persons confirms that A1C 
levels   are   strongly   associated   with   subsequent 
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mortality in both men and women without prior 
diabetes diagnosis (Brewer et al., 2008).
Glycosylated hemoglobin
Hemoglobin   (Hb)   is   made   up   two   globin 
dimmers each with a heme moiety. HbA comprises 
97% of the total Hb and hemoglobin A1C  is an 
irreversible complex that forms when glucose binds 
to   hemoglobin   (Gallagher   et   al.,   2009).   HbA1C 
constitutes   about   60-80%   of   total   glycated 
hemoglobin (Tran et al., 2004).
First 60 years ago it was shown by Allen that 
HbA   contains   three   minor   components;   HbA1c, 
HbA1b,  and HbA1c  (or A1C). A1C  is nonenzymatic 
glycated product of the hemoglobin beta-chain at the 
valine terminal residue. The number 1C represents 
the order of Hb detection on chromatography (Kahn 
& Fonseca, 2008; Tran et al., 2004). HbA1C was first 
separated by Huisman and Meyring in 1958 and was 
identified as a glycoprotein by Bokchin and Gallop 
in 1968, but it was characterized as an unusual 
hemoglobin" in diabetic patients by Iranian scientist 
"Samuel Rahbar" in 1969 who noted that diabetes is 
clearly associated with an elevation in glycated 
hemoglobin. 
The use of HbA1C for control of blood sugar in 
diabetic   patients   was   proposed   by   Cerami   and 
Koenig in 1976 (Kahn & Fonseca, 2008; Tran et al., 
2004).   After   clinical   works   in   1980s,   it   was 
introduced as a better index of diabetic control trials 
(Gallagher et al., 2009; Kahn & Fonseca., 2008). 
An important change in diabetes care occurred in 
the   1970s   and   1980s   as   two   methods   became 
available: self-monitoring of blood glucose (SMBG) 
and HbA1C testing (A1C). Regular SMBG has positive 
effect on improving glycemia particularly in testing 
the individuals treated with insulin. SMBG reflects 
the immediate plasma glucose levels, while HbA1C 
measures long-term glycemic control (Saudek et al., 
2006).
HbA1C assays and limitations
Standardization of  A1C  measurement has been 
proposed in different countries to ensure accuracy in 
A1C results (Gallagher et al., 2009).
Assays for A1C use technologies based on either 
charge   differences   high   performance   liquid 
chromatography   (HPLC)   or   structure   (boronate 
affinity or immunoassay combined with general 
chemistry) and newly techniques based on combined 
immunoassay and general chemistry (Bode et al., 
2007).
In   past   decades,   the   trials   such   as   DCCT 
(Diabetes   Control  and  Complications   Trial)  and 
UKPDS   (UK   Prospective   Diabetes   Study) 
considered A1C as the gold standard of diabetes care 
(Dailey, 2009; Gallagher et al., 2009; Saudek et al., 
2006). Furthermore, the programs such as NGSP 
(National   Glycohemoglobin   Standardization 
Program)   and   associations   such   as   AACC 
(American   Association   for   Clinical   Chemistry) 
(Kahn   &   Fonseca,   2004)   have   worked   on 
standardization of A1C  values leading to present 
methods in measurement of A1C.  Recently, NGSP-
certifies rapid HbA1C assays have become available, 
allowing office and home testing (Saudek et al., 
2006).
Because A1C is based on hemoglobin, quantities 
or qualitative variations in hemoglobin can affect the 
A1C value and interpreting of results (Bloomgarden, 
2008). These variations include the case of reduced 
total Hb or turnover of red blood cells that cause 
reduced level of A1C even in the presence of high 
ambient   plasma   glucose   (Tran   et   al.,   2004) 
Generally, abnormal results of A1C test may get with 
sickle-cell   disease,   glucose-6-phospahte 
dehydrogenase deficiency, B12 or folate deficiency, 
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alcoholism,   chronic   renal   or   liver   disease, 
splenectomy or splenomegaly, chronic opiate use, 
large doses of aspirin, vitamin C and vitamin E 
supplements, creatin and drugs such as dapsone, 
ribavirine and so forth (Gallagher et al., 2009; Tran 
et al., 2004). Besides HbA of human erythrocytes 
contain other hemoglobins such as HbA2 and fetal 
hemoglobin (HbF). Figure 1 questions remain about 
exact   mechanisms   of   these   abnormal   situations 
(Gallagher  et  al.,  2009;  Goldstein et  al.,  2004; 
Saudeket al., 2006).
Figure 1: Factors influencing A1C
It seems that HbA1C has negative correlation with 
age (El-Kebbi et al., 2003; Gilliland et al., 2002) and 
shift in the onset of diabetes to younger ages is 
notable.   This   difference   may   be   the   result   of 
differences among age groups in treatment strategies 
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or poor control as well as visit frequency in older 
people (Gilliland et al., 2002).
Monitoring value and recommended ranges 
A1C  is nonenzymatic glycated product of the 
hemoglobin beta-chain and it is normally present at 
low levels in circulating red cells because of the 
glycosylation reaction between Hb and circulating 
glucose,   but   in   the   presence   of   excess   plasma 
glucose this glycation is increased, thus making the 
A1C a useful index of glycemic control (Tran et al., 
2004).
Average life span of erythrocytes is 117 days in 
men and 106 days in women. Because erythrocytes 
are freely permeable to glucose, the level of HbA1C 
in a blood sample provides a glycemic history of the 
previous 120 days, therefore diabetic patients are 
recommended   to   be   tested   every   3   months 
(Gallagher  et  al.,  2009;  Goldstein  et  al.,  2004; 
Smaldone, 2008). 
"American   Diabetic   Association"   (ADA) 
recommends measuring HbA1C at least 2 times per 
year for patients who have met their therapeutic 
goals and quarterly for patients who have not met 
their glycemic goals or have changed their therapies 
(Dailey, 2009; Gallagher et al., 2009).
The normal range of HbA1C  test for nondiabetic 
people is between 4-6% (Goldstein et al., 2004). In 
diabetic   patients   the   recommended   value   by 
"International Diabetes Federation" and "American 
College of Endocrinology" is below 6.5%, while 
acceptable level of ADA is below 7% in general but 
suggesting an A1C level as close to normal (<6%) as 
possible without causing significant hypoglycemia 
in individual patients (Cefalu, 2008). The suggested 
target   hemoglobin   A1C  level   by   "American 
Association of Clinical Endocrinology" is £ 6.5%. 
Their   guideline   states  that  the  normalization  of 
blood glucose levels should be the goal, while the 
guideline   of   "American   Academy   of   Family 
Physicians" states that due to differences in patients' 
life   expectancies   and   co-morbid   conditions,   a 
uniform target A1C level for all patients with type 2 
diabetes   is   inappropriate.   The   guideline   of 
"American   Geriatrics   Society"   suggests 
"individualized" A1C levels for older persons. This 
organization   accepts  £ 7%   level   for   relatively 
healthy adults with good functional status and 8% 
level for others with a life expectancy of less than 5 
years   or  the  risk  of  intensive  glycemic  control 
outweighs the benefit. Other organizations such as 
"Canadian Diabetes Association" and "Institute for 
Clinical   Systems   Improvement"   recommend 
"individualized"   goals   for   certain   populations 
(Cefalu, 2008; Qaseem et al, 2007). It is difficult to 
achieve or maintain target A1C levels and only about 
a  third  of diagnosed  patients   achieve   that  goal 
(Dailey, 2009; Kahn & Fonseca, 2008; Tran et al, 
2004). In general, level of approximately 7% is 
confirmed   in   trials   on   high-risk   populations, 
specially   the   use   of   aggressive   pharmacological 
therapy is under consideration (Cefalu, 2008). 
Epidemiologic   studies   suggest   that   each   1% 
increase in the A1C value is associated with a 18% 
increase   in   the   relative   risk   of   cardiovascular 
diseases for patients with type 2 diabetes (Buse et 
al., 2007) and with 15% for type I diabetes (Selvin 
et al., 2004). In normoglycemic range, this risk has 
been estimated about 20-30% (Day & Bailey, 2007).
Meta-analysis of clinical trials shows that every 
1% reduction in A1C, lowers the risk of developing 
eye, kidney complications, and neuropathy by 40%. 
This reduction for myocardial infarction (MI) is 
14% (Bode, 2007; Selvin, 2004).
The   meta-analysis   of   observational   studies 
indicates   that   the   relationship   of   A1C  with 
cardiovascular diseases in diabetic persons is less 
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clear   than   microvascular   diseases,   thus   further 
randomized trials is necessary (Cefalu, 2008; Selvin, 
2004).
Some   authors   believe   that   optimal   diabetes 
management   involves   adjunct   control   of   fasting 
(FBS);   preprandial,   postprandial   glucose   (PPG) 
levels. A1C can not be used to identify whether an 
abnormal glycemic level is primarily due to high 
FBS or high PPG levels. In fact, elevated A1C signals 
a need for a change in therapy (not what type 
changes), whereas PPG is increasingly important as 
A1C  decreases toward target levels (Dailey, 2009; 
Day   &   Bailey,   2007;  Shiraiwa   et   al.,   2005). 
Continuously,   A1C  is   the   gold   standard   for 
monitoring   glycemic   control   and   serves   as   an 
indicator for diabetic related diseases.
SUMMARY
HbA1C measuring is consistently the best way for 
monitoring   glycemic   control   over   time   and 
predicting   of   diabetic   complications.   Different 
organizations have different guidelines for glycemic 
control, but most of them accept a target A1C level of 
approximately 7% with specific or "individualized" 
goal especially for older patients or in the presence 
of comorbid conditions. They state that although A1C 
measures   mean   glycemic   exposure   during   the 
preceding   2-3   months,   it   does   not   provide 
information about day-to-day changes in glucose 
levels. Regular SMBG is presented as an important 
adjunct to A1C, because it can distinguish among 
fasting, preprandial, and postprandial hyperglycemia 
and   can   identify   hypoglycemia   and   provide 
necessary changes in medication, food and activity 
choices. A1C has good standardization in comparison 
with   FBS   and   other   parameters,   although 
nonglycemic factors affecting A1C should be taken 
into account (Bloomgarden, 2008).
Due to attention to recent advances in rapid A1C 
assays allowing immediate feedback changes, and 
improving   community-based   public   health 
interventions   through   nutrition   and   exercise 
programs (Goldhaber et al., 2003), better future for 
glycemic  control  of diabetic  population will  be 
imaginable.
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